HomeCompareDZGH vs ABBV

DZGH vs ABBV: Dividend Comparison 2026

DZGH yields 33.33% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DZGH wins by $56.4K in total portfolio value
10 years
DZGH
DZGH
● Live price
33.33%
Share price
$6.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$160.1K
Annual income
$23,203.52
Full DZGH calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — DZGH vs ABBV

📍 DZGH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDZGHABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DZGH + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DZGH pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DZGH
Annual income on $10K today (after 15% tax)
$2,833.33/yr
After 10yr DRIP, annual income (after tax)
$19,722.99/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $1,803.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DZGH + ABBV for your $10,000?

DZGH: 50%ABBV: 50%
100% ABBV50/50100% DZGH
Portfolio after 10yr
$131.9K
Annual income
$24,264.15/yr
Blended yield
18.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DZGH
No analyst data
Altman Z
0.0
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DZGH buys
0
ABBV buys
0
No recent congressional trades found for DZGH or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDZGHABBV
Forward yield33.33%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$160.1K$103.7K
Annual income after 10y$23,203.52$25,324.79
Total dividends collected$113.6K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DZGH vs ABBV ($10,000, DRIP)

YearDZGH PortfolioDZGH Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$14,033$3,333.33$11,555$434.96+$2.5KDZGH
2$19,387$4,371.75$13,485$635.47+$5.9KDZGH
3$26,389$5,644.57$15,933$937.67+$10.5KDZGH
4$35,417$7,180.46$19,118$1,400.80+$16.3KDZGH
5$46,902$9,006.44$23,384$2,125.24+$23.5KDZGH
6$61,333$11,146.93$29,290$3,286.81+$32.0KDZGH
7$79,249$13,622.82$37,776$5,205.38+$41.5KDZGH
8$101,247$16,450.69$50,495$8,488.44+$50.8KDZGH
9$127,976$19,642.17$70,497$14,346.44+$57.5KDZGH
10$160,138$23,203.52$103,718$25,324.79+$56.4KDZGH

DZGH vs ABBV: Complete Analysis 2026

DZGHStock

JJY Holding Group does not have significant operations. It intends to be in the business that involves trading agricultural products, food processing, and be a supply chain for supermarkets. The company was formerly known as Beesfree, Inc. JJY Holding Group is based in Shanghai, the People's Republic of China.

Full DZGH Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DZGH vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DZGH vs SCHDDZGH vs JEPIDZGH vs ODZGH vs KODZGH vs MAINDZGH vs JNJDZGH vs MRKDZGH vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.